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Background: Transradial access (TRA) has been associated with reduced access site
related bleeding complications and mortality following percutaneous coronary inter-
vention (PCI), although it is unclear whether these observed beneﬁts are inﬂuenced by
baseline bleeding risk. We have therefore investigated this relationship by quantifying
baseline bleeding risk, TRA utilisation and procedure related outcomes in a large
number of patients undergoing PCI enrolled in the British Cardiovascular Intervention
Society (BCIS)database of PCI procedures performed in the United Kingdom.
Methods: Baseline bleeding risk was calculated using a modiﬁcation of the Mehran
bleeding risk scores in 348,689 PCI procedures undertaken in patients in the United
Kingdom between 2006 - 2011. Four categories for bleeding risk were deﬁned for the
modiﬁed Mehran risk score (MMRS): low (<10), moderate (10-14), high (15-19), and
very high (>20). The impact of baseline bleeding risk on 30 day mortality and its
relationship with access site was studied.
Results: TRA was independently associated with a 35% reduction in 30-day mortality
(OR 0.65, 95% CI 0.59-0.72, p<0.0001), with the magnitude of mortality reduction
related to baseline bleeding risk (MMRS < 10: OR 0.73; 95% CI 0.62-0.86); MMRS
>20 (OR 0.53; 95% CI 0.47-0.61). In patients with a MMRS <10, TRA was used in
71,771/166083 PCI procedures (43.2%) compared to 8,655/21559 (40.1%) patients
with MMRS >20, illustrating that TRA was used less in those at highest risk from
bleeding complications (P<0.0001).
Conclusions: TRA is independently associated with a reduction in 30-day mortality
and the magnitude of this mortality effect relates to baseline bleeding risk, with those
at highest risk of bleeding complications gaining the greatest beneﬁt from adoption of
the TRA during PCI. Paradoxically, use of TRA was lower in those patients most at
risk of bleeding complications. Our data suggests that adopting optimal acess site
practice guided by simple assessment of baseline bleeding risk, has the potential to
signiﬁcantly improve PCI related patient outcomes.
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Background: Suboptimal myocardial reperfusion in pts with STEMI undergoing
primary PCI is common, and results in increased infarct size and mortality. The
MGuard is a novel thin strut bare metal stent with a PET mesh covering designed to
trap and exclude thrombus and friable atheromatous debris prior to distal emboliza-
tion. We performed a prospective, randomized, multicenter trial to evaluate whether
use of the MGuard stent improves myocardial reperfusion in pts with STEMI
undergoing primary PCI.
Methods: Pts with symptoms of AMI undergoing PCI of a single de novo native
coronary lesion were eligible for enrollment, and were randomized 1:1 to PCI withB14 JACC Vol 62/18/Suppl B j October 27–Noveither the MGuard stent or any commercially available DES or BMS. The primary
endpoint was the rate of complete (70%) ST-segment resolution (STR) 60-90 mins
post-procedure. Secondary endpoints included TIMI ﬂow, clinical outcomes through 1
year, and lumen late loss and binary restenosis at 13 months in 50 MGuard patients.
Results: The primary endpoint of post-procedure complete ST-segment resolution
was signiﬁcantly improved in patients randomized to the MGuard stent compared with
control patients (57.8% vs. 44.7%; p¼0.008). The MGuard stent also resulted in
superior rates of TIMI-3 ﬂow (91.7% vs. 82.9%, p¼0.006). Mortality (0% vs. 1.9%,
p¼0.06) and major adverse cardiac events (1.8% vs. 2.3%, p¼0.75) at 30 days were
not signiﬁcantly different between patients randomized to the MGuard stent and
control stent, respectively. Twelve month follow-up is ongoing.
Conclusions: MASTER is the ﬁrst large randomized trial evaluating the ability of
a novel mesh covered stent to improve myocardial reperfusion in patients with STEMI
undergoing primary PCI. The MGuard embolic protection stent compared with
conventional metal stents resulted in superior rates of epicardial coronary ﬂow and
complete STR. Complete analysis of the ﬁnal 12-month clinical results and the 13-
month angiographic endpoints will be presented at the meeting.
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Background: Compared with trans-femoral access (TFA), trans-radial access (TRA)
reduces mortality in ST elevation MI (STEMI). Whether TRA confers a mortality
beneﬁt in non-ST elevation MI (NSTEMI) is unclear. This study sought to compare
TRA versus TFA for percutaneous coronary intervention (PCI) in patients with
NSTEMI.
Methods: We examined an observational cohort of 10,095 patients with NSTEMI
treated with PCI between 2005-2011 at 8 tertiary cardiac centers in London, UK. The
following clinical outcomes were analyzed: all cause mortality; MACE (major adverse
cardiovascular events); and NACE (net adverse cardiovascular events: MACE
combined with bleeding events).
Results: Over a 6 year period, TRA was used in 23% of patients. TRA was associated
with a signiﬁcant reduction in bleeding (0.23% vs. 0.97%, p¼0.001) and access site
complications (0.35% vs. 1.00%, p¼0.003). Multivariate analysis identiﬁed TRA as
independent predictor for in-hospital MACE (OR¼0.60, 95% CI:0.38-0.93,
p¼0.023); in-hospital NACE (OR¼0.68, 95% CI:0.45-0.97, p¼0.033); 30-day
mortality (HR¼0.55, 95% CI:0.31-0.97, p¼0.041); 6-month mortality (HR¼0.59,
95% CI:0.41-0.87, p¼0.007); 1-year mortality (HR¼0.74, 95% CI:0.55-0.99,
p¼0.042). When excluding patients with bleeding events, TRA still remained an
independent predictor for survival.Conclusions: In this large registry of patients with NSTEMI, TRA appears to be an
independent predictor for survival. These data indicate that other factors besides
a reduction in bleeding may be contributory and lend support for prospective
randomized evaluation of TRA in NSTEMI.ember 1, 2013 j TCT Abstracts/ORAL/STEMI and High Risk Patients
